ACRIVON THERAPEUTICS INC. - COMMON STOCK

Acrivon Therapeutics Announces $130 Million Private Placement Financing

09 4 2024 04:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

28 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

05 3 2024 13:30:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

04 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

27 2 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

08 2 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 2 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 1 2024 13:00:24 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

04 1 2024 05:00:01 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

03 1 2024 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 11 2023 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

21 11 2023 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

09 11 2023 05:01:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

16 10 2023 05:00:01 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 9 2023 13:05:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

19 9 2023 13:32:13 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

05 9 2023 13:05:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics to Participate in Two Investor Conferences in September

30 8 2023 05:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

17 8 2023 13:00:00 提供 Nasdaq GlobeNewswire

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

11 8 2023 04:00:00 提供 Nasdaq GlobeNewswire